Navigation Links
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Date:1/15/2009

rand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the FDA's timely review and approval of Bepreve, ISTA's belief the FDA will review and take action on Bepreve within ten months of filing and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual resul
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... RnRMarketResearch.com adds "Pemphigus - ... of 68 pages with latest updates, data and ... The report "Pemphigus - Pipeline Review, H1 2015" report ... for Pemphigus , complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
(Date:3/31/2015)... KENNEBUNK, Maine , March 31, 2015 /PRNewswire/ ... aggregated enrollment in Medicare Advantage (MA) plans in ... approximately 17.3 million people were enrolled in Medicare ... of more than 1.3 million members year-over-year.  54.3 ... the Centers for Medicare and Medicaid Services (CMS), ...
(Date:3/31/2015)...  SynCardia Systems, Inc. has received FDA approval to ... the effective use of its 50cc SynCardia temporary Total ... The FDA approval will allow SynCardia to launch ... patients. Patients enrolled in this study will receive the ... a donor heart transplant. (Caution-In the United States, ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... 2011 Reportlinker.com announces that a new market ... Hospital Angiography Census ... most comprehensive European market report on the installed ... R&F, Angiography, CT, MRI,) and radiology IT systems ...
... China, Jan. 20, 2011 /PRNewswire-Asia/ -- Winner Medical ... Medical") a leading manufacturer of medical dressings, medical ... PurCotton® products in China, today announced that one ... ("Huanggang Cotton"), was recently awarded a Cotton Processing ...
Cached Medicine Technology:Reportlinker Adds Hospital Angiography Census 2Reportlinker Adds Hospital Angiography Census 3Winner Medical Obtains Cotton Processing Certificate from the State Development and Reform Commission 2Winner Medical Obtains Cotton Processing Certificate from the State Development and Reform Commission 3
(Date:3/31/2015)... Researchers at UC Davis have ... how human livers heal. The difference centers on ... Normally, mouse PPARa is far more active and ... quickly regenerate damaged livers. However, the research shows ... boost the regenerative effects of human PPARa. The ...
(Date:3/31/2015)... Mission, TX (PRWEB) March 31, 2015 One of ... would be a visit to Mount Kilauea on the big island. ... the few places where you can see molten lava slowly oozing ... spectacles on earth. , One place you would never ... in the flat, arid terrain of Mission, Texas -- until now. ...
(Date:3/31/2015)... 31, 2015 Indosoft, Inc., developers of ... the availability of SIP over TCP configuration for all SIP ... offering a full contact center ACD (Automatic Call ... Adding SIP over TCP support to all SIP devices gives ... The history of Voice over IP (VoIP) has primarily involved ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 National ... physical, social and psychological benefits of participating in ... thousands of adaptive sports athletes that adapt, believe ... encourage support for inclusive fitness and inclusive athletics ... in participating in adaptive sports and advocate for ...
(Date:3/31/2015)... March 31, 2015 Array Health ... technology, has announced that Lance Hood, Senior Director of ... Private Exchange Forum on April 1, 2015. The session, ... Benaissance, will address how employers can streamline and simplify ... , WHAT: “ Optimizing Employee and Employer Needs in ...
Breaking Medicine News(10 mins):Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 3Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 4Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 3Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2Health News:April is National Adaptive Sports Month 2Health News:April is National Adaptive Sports Month 3Health News:Array Health’s Senior Director of Marketing to Co-Present with Benaissance at The Institute for HealthCare Consumerism Private Exchange Forum 2
... 2009 ,Potential Benefits of Intermittent Androgen Suppression Therapy ... of the Literature, is the title of an article ... European Urology , the official journal of the European ... the efficacy and tolerability of intermittent androgen deprivation (IAD) ...
... team made up of mental health professionals, emergency response ... has published the results of a study that shows ... Hurricane Katrina. The Category 3 storm ravaged the Gulf ... a recent issue of the Journal of the ...
... a multi-bed hospital room dramatically increases the risk of acquiring ... A new study led by infectious diseases expert Dr. Dick ... C. difficile ( Clostridium difficile ) rises with ... in a two, three or four-bedded room, each time you ...
... ,A new study shows that poor lung function ... factors, including birth weight, height, and gender. Researchers from Newcastle ... patients, all aged 14 years. Follow-up data also were obtained ... Results showed that several factors were related to poorer lung ...
... from the Society of Breast Imaging (SBI) and the ... published in the January issue of the Journal ... that breast cancer screening should begin at age 40 ... appropriate utilization of medical imaging modalities such as mammography, ...
... to sexual arousal, whereas in men, the responses of ... each other, according to Assistant Professor Meredith Chivers, from ... Michael Seto, Martin Lalumire, Ellen Laan, and Teresa Grimbos. ... ratings and physiological measures of sexual arousal in men ...
Cached Medicine News:Health News:Intermittent androgen deprivation at least as effective as continuous androgen deprivation 2Health News:Sharing a hospital room increases risk of 'super bugs' 2Health News:News briefs from the January issue of Chest 2Health News:New SBI and ACR recommendations suggest breast cancer screening should begin at age 40 2Health News:Women's bodies and minds agree less than men's on what's sexy 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: